Precision Mental Health: Develop Tools to Inform Treatment Selection in Depression (UG3/UH3 Clinical Trial Optional)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website    Save this grant

Next deadline: Oct 18, 2023 (Full proposal)

Later deadlines: Oct 18, 2024 (Full proposal)

Grant amount: Up to US $8,500,000

Fields of work: Mental Health & Psychiatric Diseases Depression/Anxiety

Applicant type: Government Entity, Nonprofit, For-Profit Business, Indigenous Group

Funding uses: Research, Project / Program

Location of project: Anywhere in the world

Location of residency: Anywhere in the world


NOTE: All applications are due by 5:00 PM local time of applicant organization. 

The goal of this phased FOA (either R33/R61 or UG3/UH3) is to accelerate the development of sensitive biomarkers/tools to predict individual treatment-response between two or more existing treatments for depression. In phase 1 (up to 2 years) preliminary studies (e.g., retrospective secondary analyses of data from completed clinical trials and/or in nimble, fast-fail pilot studies) will de-risk the test technology demonstrating that there is enough signal for clinical utility (futility analyses, ROC curves, and/or effect size will be evaluated as go/no-go criteria). Phase 2 (up to 5 years) innovators will prospectively test the efficacy of the biomarker/tool in large-scale biomarker/tool-stratified clinical trials with the goal of beating standard-of-care decision-making (i.e., clinician/patient treatment assignment will be the CTRL group vs the test).

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Forecasted Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih) help icon

This page was last reviewed June 06, 2023 and last updated June 05, 2023